Is MEDP Worth Buying as Growth Collides With a Premium Valuation?

Medpace Holdings, Inc. MEDP combines double-digit earnings growth, resilient profitability and improving bookings with a valuation far above industry and market levels.

The central question is whether its operating quality and 2027 pipeline justify that premium or whether uneven conversion and cancellation risk favor a more selective entry point.

MEDP’s Growth Profile Remains Compelling

The Zacks Consensus Estimate calls for 2026 sales growth of 12.4% and earnings growth of 14.6%, following roughly 20% revenue growth in 2025. That outlook points to continued expansion even as the pace normalizes from the prior year.

Image Source: Zacks Investment Research

Medpace’s full-service model and centralized operating structure support consistent execution across clinical programs. Its disciplined cost base has also helped earnings grow without sacrificing profitability. Larger peers such as IQVIA Holdings Inc. IQV and ICON plc ICLR show how scale and end-to-end clinical capabilities remain central competitive factors in the contract research market.

Medpace’s Pipeline Offers a 2027 Catalyst

Second-quarter net new business awards reached a record $795.7 million, up 28.2% year over year, while request-for-proposal activity increased sequentially and year over year. Ending backlog was $3.01 billion, with about $1.96 billion expected to convert over the next 12 months.

The benefit will not arrive all at once. Many recently awarded programs remain in pre-backlog, and some studies need time to move from notification to active work. That makes the current pipeline more relevant to 2027 than to an immediate revenue acceleration.

MEDP’s Margins and Cash Add Support

Second-quarter EBITDA rose 17.6% to $153.4 million, and the EBITDA margin held at 21.7% versus 21.6% a year earlier. Free cash flow reached $138.1 million after capital expenditures.

Medpace ended June with $502.7 million in cash, no debt and $527 million remaining under its repurchase authorization. That liquidity gives the company room to fund hiring, technology spending and campus investment while retaining flexibility for additional capital returns.

Medpace’s Premium Valuation Limits Flexibility

MEDP trades at 31.8X forward 12-month earnings, compared with 16.1X for the Zacks sub-industry and 20.6X for both the Zacks Medical sector and the S&P 500. Its price-to-sales ratio of 5.8 and EV-to-EBITDA multiple of 27.8 also stand well above the industry’s 1.4 and 2.2, respectively.

Image Source: Zacks Investment Research

Those premiums leave little room for execution slippage. Continued earnings delivery, backlog conversion and stable margins are needed to support the current multiple, while any bookings or guidance disappointment could pressure the shares.

MEDP Still Faces Uneven Visibility

The top five customers generated 31% of trailing 12-month revenues. Cardiometabolic award activity has moderated, while oncology represented more than half of recent bookings and award notifications.

That mix shift could lengthen conversion timing, and cancellations remain difficult to predict. Reimbursed out-of-pocket expenses were about 43% of second-quarter revenues, making reported growth and margin trends harder to interpret when pass-through activity changes.

MEDP’s Quality Signals Favor Selectivity

MEDP’s growth, margins and balance sheet support a favorable operating view, but the premium valuation and uneven booking visibility argue against an unqualified stance.

The stock carries a Zacks Rank #2 (Buy) and a Growth Score of A, indicating positive earnings-estimate momentum and attractive growth characteristics. Its Value Score of D and Momentum Score of C are less supportive, while the VGM Score of B offers a balanced overall profile. Together, these signals favor selectivity rather than chasing the stock at any price.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research